Molecular-weight-dependent effects of nonanticoagulant heparins on allergic airway responses

Journal of Applied Physiology

Volumn 86, Issue 2, 1999, Pages 549-557

  Campo, Carlos ^a   Molinari, Jussara F ^a   Ungo, Jaime ^a   Ahmed, Tahir ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Airway hyperresponsiveness; Antigen induced bronchoconstriction; Asthma

Indexed keywords

HEPARIN;

AIRWAY RESISTANCE; ALLERGY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; CONTROLLED STUDY; IMMUNOREGULATION; LUNG LAVAGE; MAST CELL; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; SHEEP; VASCULAR RESISTANCE;

EID: 0032982085     PISSN: 87507587     EISSN: None     Source Type: Journal    
DOI: 10.1152/jappl.1999.86.2.549     Document Type: Article

References (46)

1. Abraham, W. M., M. K. Abraham, and T. Ahmed. Protective effect of heparin on immunologically induced tracheal smooth muscle contraction in vitro. Int. Arch. Allergy Immunol. 110: 79-84, 1996.
2. Ahmed, T., W. M. Abraham, and J. D'Brot. Effects of inhaled heparin on immunologic and non-immunologic bronchoconstrictor responses in sheep. Am. Rev. Respir. Dis. 145: 566-570, 1992.
3. Ahmed, T., C. Campo, M. K. Abraham, J. F. Molinari, W. M. Abraham, D. Ashkin, T. Syriste, L. O. Andersson, and C. M. Svahn. Inhibition of antigen-induced acute bronchoconstriction, airway hyperresponsiveness, and mast cell degranulation by a nonanticoagulant heparin: comparison with a low molecular weight heparin. Am. J. Respir. Crit. Care Med. 155: 1848-1855, 1997.
4. Ahmed, T., J. D'Brot, W. M. Abraham, J. Lucio, R. Mendelssohn, M. J. Robinson, S. Shakir, and B. SanPedro. Heterogeneity of allergic airway responses in sheep: differences in signal transduction? Am. J. Respir. Crit. Care Med. 154: 843-849, 1996.
5. 2 receptors in airway reactions to histamine in conscious sheep. J. Appl. Physiol. 49: 826-833, 1980.
6. Ahmed, T., J. Garrigo, and I. Danta. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N. Engl. J. Med. 329: 90-95, 1993.
7. 3-mediated mast cell degranulation? J. Appl. Physiol. 76: 893-901, 1994.
8. Andersson, L. O., T. W. Barrowcliffe, E. Holmer, E. A. Johnson, and G. E. C. Sims. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix bound antithrombin III by gel filtration. Thromb. Res. 9: 575-583, 1976.
9. Barzu, T., J. L. Van Rijn, M. Petitou, P. Molho, G. Tobelem, and J. P. Caen. Endothelial binding sites for heparin. Specificity and role in heparin neutralization. Biochem. J. 238: 847-854, 1986.
10. Bowler, S. D., S. M. Smith, and P. S. Lavercombe. Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. Am. Rev. Respir. Dis. 147: 160-163, 1993.
11. Burg, M., T. Ostendorf, A. Mooney, K. M. Koch, and J. Floege. Treatment of experimental mesangioproliferative glomerulonephritis with non-anticoagulant heparin: therapeutic efficacy and safety. Lab. Invest. 76: 505-516, 1997.
12. Castellot, J. J., Jr., D. L. Cochran, and M. J. Karnovsky. Effect of heparin on vascular smooth muscle cells. 1. Cell metabolism. J. Cell. Physiol. 124: 21-28, 1985.
13. Cifonelli, J. A. The relationship of molecular weight and sulfate content distribution to anticoagulant activity of heparin preparations. Carbohydr. Res. 37: 145-154, 1974.
14. Diamant, Z., M. C. Timmers, H. van der Veen, C. P. Page, F. J. van der Meer, and P. J. Sterk. Effect of inhaled heparin on allergen-induced early and late asthmatic responses in patients with atopic asthma. Am. J. Respir. Crit. Care Med. 153: 1790-1795, 1996.
15. Dolowitz, D. A., and T. F. Dougherty. The use of heparin as an anti-inflammatory agent. Laryngoscope 70: 873-884, 1960.
16. Erger, R. A., and T. B. Casale. Comparison of methodologies to measure human lung histamine. J. Immunol. Methods 152: 115-121, 1992.
17. Faham, S., R. E. Hileman, J. R. Fromm, R. J. Linhardt, and D. C. Rees. Heparin structure and interactions with basic fibroblast growth factor. Science 271: 1116-1120, 1996.
18. Fareed, J., J. M. Walenga, D. Hoppensteadt, A. Racanelli, and E. Coyne. Chemical and biological heterogeneity in low molecular weight heparins: implications for clinical use and standardization. Semin. Thromb. Hemost. 15: 440-463, 1989.
19. Folkman, J., and D. E. Ingber. Angiogenesis: regulatory role of heparin and related molecules. In: Heparin, edited by D. A. Lane and U. Lindahl. London: Arnold, 1989, p. 317-333.
20. Garrigo, J., I. Danta, and T. Ahmed. Time course of the protective effect of inhaled heparin on exercise-induced asthma. Am. J. Respir. Crit. Care Med. 153: 1702-1707, 1996.
21. Jacques, L. B. Heparins-anionic polyelectrolyte drugs. Pharmacol. Rev. 31: 99-166, 1979.
22. Jones, C. A., K. A. Williams, J. J. Finlay-Jones, and P. H. Hart. Interleukin 4 production by human amnion epithelial cells and regulation of its activity by glycosaminoglycan binding. Biol. Reprod. 52: 839-847, 1995.
23. Laghi Passini, F., A. L. Pasqui, L. Ceccatelli, P. L. Capecchi, A. Orrico, and T. DiPerri. Heparin inhibition of polymorphonuclear leukocyte activation in vitro. A possible pharmacological approach to granulocyte-mediated vascular damage. Thromb. Res. 35: 527-537, 1984.
24. Lantz, M., H. Thysell, E. Nilsson, and I. Olsson. On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. J. Clin. Invest. 88: 2026-2031, 1991.
25. Lider, O., Y. A. Mekori, T. Miller, R. Bar-Tana, I. Vlodavsky, E. Baharav, I. R. Cohen, and Y. Naparstek. Inhibition of T-lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity. Eur. J. Immunol. 20: 493-499, 1990.
26. Lindahl, U. Biosynthesis of heparin and related polysaccharides. In: Heparin, Chemical and Biological Properties, Clinical Applications, edited by D. A. Lane and U. Lindahl. Boca Raton, FL: CRC, 1989, p. 159-189.
27. Lindahl, U., G. Bäckström, and L. Thunberg. The antithrombin-binding sequence in heparin. Identification of an essential 6-O-sulfate group. J. Biol. Chem. 258: 9826-9830, 1983.
28. Lindahl, U., G. Bäckström, L. Thunberg, and I. G. Leder. Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin. Proc. Natl. Acad. Sci. USA 77: 6551-6555, 1980.
29. Linhardt, R. J., and D. Loganathan. Heparin, heparinoids and heparin oligosaccharides: structure and biological activities. In: Biomimetic Polymers, edited by C. G. Gebelein. New York: Plenum, 1990, p. 135-173.
30. Lortat-Jacob, H., F. Baltzer, and J. A. Grimaud. Heparin decreases the blood clearance of interferon-γ and increases its activity by limiting the processing of its carboxyl-terminal sequence. J Biol. Chem. 271: 16139-16143, 1996.
31. Lucio, J., J. D'Brot, C. B. Guo, W. M. Abraham, L. M. Lichtenstein, A. Kagey-Sobotka, and T. Ahmed. Immunologic mast cell-mediated responses and histamine release are attenuated by heparin. J. Appl. Physiol. 73: 1093-1101, 1992.
32. Martinez-Salas, J., R. Mendelssohn, W. M. Abraham, B. Hsiao, and T. Ahmed. Inhibition of allergic airway responses by inhaled low-molecular weight heparins: molecular weight dependence. J. Appl. Physiol. 84: 222-228, 1998.
33. Matzner, Y., G. Marx, R. Drexler, and A. Eldor. The inhibitory effect of heparin and related glycosaminoglycans on neutrophil chemotaxis. Thromb. Haemost. 52: 134-137, 1984.
34. Molinari, J. F., C. Campo, S. Shakir, and T. Ahmed. Inhibition of antigen-induced airway hyperresponsiveness by ultralow molecular weight heparin. Am. J. Respir. Crit. Care Med. 157: 887-893, 1998.
35. Nelson, R. M., O. Cecconi, W. G. Roberts, A. Aruffo, R. J. Linhardt, and M. P. Bevilacqua. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 82: 3253-3258, 1993.
36. O'Reilly, R. A. Anticoagulant, antithrombotic and thrombolytic drug. In: The Pharmacological Basis of Therapeutics, edited by A. G. Goodman, L. S. Goodman, and A. Gilman. New York: Macmillan, 1980, p. 1348-1352.
37. Palm, M., and C. Mattsson. Pharmacokinetics of fragmin. A comparative study in the rabbit of its high and low affinity forms of antithrombin. Thromb. Res. 48: 51-62, 1987.
38. Palm, M., C. Mattson, C. M. Svahn, and M. Weber. Bleeding times in rats treated with heparin, heparin fragments of high and low anticoagulant activity and chemically modified heparin fragments of low anticoagulant activity. Thromb. Haemost. 64: 127-132, 1990.
39. Pukac, L. A., G. M. Hirsch, J. C. Lormeau, M. Petitou, J. Choay, and M. J. Karnovsky. Antiproliferative effects of novel, nonanticoagulant heparin derivatives on vascular smooth muscle cells in vitro and in vivo. Am. J. Pathol. 139: 1501-1509, 1991.
40. Sakuragawa, N., and K. Takahashi. Comparative studies on properties of unfractionated and low molecular weight heparin. Semin. Thromb. Hemost. 16: 5-11, 1990.
41. Schwartz, L. B., and T. R. Bradford. Regulation of tryptase from human lung mast cells by heparin. Stabilization of the active tetramer. J. Biol. Chem. 261: 7372-7379, 1986.
42. Schwartz, L. B., C. Riedel, J. P. Caulfield, S. I. Wasserman, and K. F. Austen. Cell association of complexes of chymase, heparin proteoglycan, and protein after degranulation by rat mast cells. J. Immunol. 126: 2071-2078, 1981.
43. Seeds, E. A. M., J. Hanss, and C. P. Page. The effect of heparin and related proteoglycans on allergen and PAF-induced eosinophil infiltration. J. Lipid Mediators 7: 269-278, 1993.
44. Völker, W., A. Böhm, A. Schmidt, C. M. Svahn, A. K. Gellerbring, C. Mattsson, S. Ekvärn, H. Robenek, and E. Buddecke. Inhibition of smooth muscle cell proliferation and neointimal growth by low-anticoagulant heparin. Arzneimittelforschung 45: 546-550, 1995.
45. Wanner, A., and M. E. Reinhart. Respiratory mechanics in conscious sheep: response to methacholine. J. Appl. Physiol. 44: 479-482, 1978.
46. Weiler, J. M., R. E. Edens, R. J. Linhardt, and D. P. Kapelanski. Heparin and modified heparin inhibit complement activation in vivo. J. Immunol. 148: 3210-3215, 1992.